Dr Srijan Jindal

Dr Srijan Jindal is a British-Indian scientist and entrepreneur whose research at the University of Liverpool formed the scientific foundation of InnotiveDx. He developed the core diagnostic technology during his PhD and postdoctoral research under Professor Doug Kell at the Institute of Systems, Molecular and Integrative Biology — work that demonstrated the feasibility of identifying urinary tract infection pathogens and their antibiotic sensitivities in under an hour, versus the 48–72 hour wait associated with traditional lab culture methods.

Srijan is Co-Founder and Chief Scientific Officer of InnotiveDx, where he leads the scientific and technical development of the company's rapid point-of-care UTI diagnostic system. UTIs affect hundreds of millions of people globally each year and account for more than 20% of all antibiotic prescriptions — making them a major driver of antimicrobial resistance. InnotiveDx's platform directly addresses this by providing comprehensive pathogen identification and antimicrobial susceptibility test results in under 60 minutes, at the point of care where no alternatives currently exist.

InnotiveDx has grown rapidly since spinning out from Liverpool, now employing more than 20 people and raising over £3 million in funding from a combination of Innovate UK grants and equity investment. The company has validated its technology against one of the largest diagnostic companies in the world, achieving over 96% agreement, and is now progressing toward large-scale clinical studies ahead of a commercial launch.